Immunoglobulin News and Research

RSS

CSL Behring presents Hizentra study data against PI at AAAAI meeting

Data presented by CSL Behring today suggest that treatment with higher dose Hizentra correlates with reduced risk of infection and missed school or work among patients with primary immunodeficiencies.

22 Mar 2011

Highmark forces patients with PIDD to switch over to specific IgG therapy

Beginning April 1, Highmark Blue Cross Blue Shield will force their insured patients with primary immunodeficiency diseases and other rare disorders to switch their prescription to a single brand of immunoglobulin, regardless of their current IgG therapy.

17 Mar 2011

Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint

Tolerx, Inc. and GlaxoSmithKline (GSK) today announced that the Phase 3 DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset autoimmune type 1 diabetes.

11 Mar 2011

Halozyme Therapeutics 2010 net loss decreases to $53.2 million

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2010.

11 Mar 2011

New research reveals how maternal antibodies block immune response to measles virus

New research that reveals how maternal antibodies block an immune response to the measles virus is a first step toward improving current childhood vaccination practices, scientists say.

1 Mar 2011

Study: Low Vitamin D levels can cause allergies in children

A study of more than 3,000 children shows that low vitamin D levels are associated with increased likelihood that children will develop allergies, according to a paper published in the February 17 online edition of the Journal of Allergy and Clinical Immunology.

25 Feb 2011

FDA approves sBLA for CSL's Hizentra to treat PI

CSL Behring announced today that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application to extend the shelf life of Hizentra, Immune Globulin Subcutaneous, 20% Liquid, from 24 months to 30 months.

24 Feb 2011

$Grifols to start construction of new plant in Spain for plasma fractionation$

Grifols to start construction of new plant in Spain for plasma fractionation

Grifols, the Spanish group which specializes in the hospital-pharmaceutical sector and is one of the world's leading producers of plasma products, will shortly start construction of a new plant representing an investment of 20 million euros that will employ about 100 people, as soon as it obtains local permits and licenses.

19 Feb 2011

Daily probiotic may help prevent upper respiratory tract infections in athletes: Research

Researchers at Loughborough University have revealed that a simple, daily probiotic might help prevent athletes catching colds during their training and competition.

2 Feb 2011

Baxter fourth quarter net income declines 26% to $423 million

Baxter International Inc. today announced its financial results for the fourth quarter of 2010, and provided its financial outlook for the first quarter and full-year 2011.

From Baxter International Inc. 27 Jan 2011

Clinical Immunology Research Laboratory at The Mount Sinai Medical Center receives Octapharma grant

Octapharma USA today announced the second grant recipient of the Octapharma 25th Anniversary Grants Program is the Clinical Immunology Research Laboratory at The Mount Sinai Medical Center. The Octapharma Grants program supports clinical or pre-clinical research focused on human protein therapies in hematology, immune therapy, intensive care and emergency medicine.

20 Jan 2011

Virdante Pharmaceuticals receives US key patent for Sialic Switch technology

Virdante Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office has granted a key patent that supports the Company's "Sialic Switch" technology for improving the anti-inflammatory activity of antibody-based drugs to treat autoimmune and inflammatory disorders.

7 Jan 2011

Scientists develop novel technology to detect immune molecules specific to Alzheimer's disease

Scientists from the Florida campus of The Scripps Research Institute, have developed a novel technology that is able to detect the presence of immune molecules specific to Alzheimer's disease in patients' blood samples. While still preliminary, the findings offer clear proof that this breakthrough technology could be used in the development of biomarkers for a range of human diseases.

6 Jan 2011

Hepatitis A scare at Long Island church

Health officials have warned that parishioners who received Holy Communion during Christmas Mass at a church on Long Island may have been exposed to hepatitis A and may need vaccinated as soon as possible. Particularly those who received Communion at the 10.30am and 12pm (local time) masses on December 25, 2010, at Our Lady of Lourdes Church in Massapequa Park should get the shots.

4 Jan 2011

OMT announces new human antibody platform using genetically engineered rats expressing human antibodies

Open Monoclonal Technology, Inc. (OMT) today announced its new human antibody platform using the first genetically engineered rats expressing a human antibody repertoire. The company, which also created the first targeted knockout rats in 2009, is now cross-breeding the knockout animals with the rats expressing human antibodies to finalize its platform.

9 Dec 2010

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Celgene International Sàrl (NASDAQ: CELG) announced that data evaluating combination therapy REVLIMID® (lenalidomide) and dexamethasone in patients with high-risk asymptomatic smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting. The study reported REVLIMID and dexamethasone prolonged time to progression.

6 Dec 2010

Radical change to Alzheimer’s management

The first disease-modifying drugs are expected to launch from 2013, radically changing the way Alzheimer’s disease is treated. With the potential to successfully slow or halt the progression of Alzheimer’s, blockbuster revenues are beckoning for such pipeline drugs, claims independent market analyst, Datamonitor.

23 Nov 2010

Grifols launches Flebogamma 10% DIF intravenous immune globulin in the U.S.

Grifols today announced availability of its recently approved Flebogamma® 10% DIF intravenous immune globulin. Grifols is a global healthcare company specializing in bioscience medicines derived from human plasma. Approval from the US Food and Drug Administration (FDA) for Flebogamma® 10% DIF was obtained in July 2010 and final approval in Europe is expected before the end of the year. Today's announcement signals widespread product availability to the US market.

22 Nov 2010

Crescent Healthcare to open infusion pharmacy in New Jersey

Crescent Healthcare today announced a planned expansion of their east coast operations in 2011. They signed a lease to open an infusion pharmacy in Totowa, New Jersey, central to providing immune globulin therapies and services to current patients in Massachusetts, Maryland, New York, New Jersey, Pennsylvania, Connecticut, Delaware, District of Columbia, and Rhode Island.

19 Nov 2010

Science and precedent do not support biosimilar approach for plasma protein therapies

The current science and experience does not support the safety and efficaciousness of a biosimilar pathway for plasma protein therapies. At a public hearing last week, the Plasma Protein Therapeutics Association (PPTA) urged the United States Food and Drug Administration (FDA) to make patient safety its top priority by adopting a global approach in its evaluation of plasma protein therapies for the biosimilars process.

15 Nov 2010